Go online to PeerView.com/NZQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitor therapy currently has a role as consolidation therapy after chemoradiation for patients with stage III, locally advanced, unresectable non–small cell lung cancer (NSCLC). Other agents and strategies are being explored in the locally advanced setting as well. Many clinical trials are also investigating the use of immune checkpoint inhibitors as neoadjuvant and adjuvant systemic therapies in earlier stages of NSCLC, and promising data have started to emerge, including from the first few phase 3 studies. With the continual expansion of immunotherapy into earlier disease settings, multidisciplinary collaboration among thoracic surgeons, medical oncologists, radiation oncologists, and the greater lung cancer care team is paramount. This PeerView Live Seminar and Practicum based on a recent live web broadcast explores the latest advances and clinical trial findings with immunotherapies, analyzes implications for surgical management of patients, and provides case-based, practical guidance for integrating immunotherapies into multimodal management of stage I-III NSCLC in the context of multidisciplinary care. Upon completion of this accredited CE activity, participants should be better able to: Characterize the mechanisms of action of immune checkpoint inhibitors and other novel cancer immunotherapies, and the rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, Discuss the current and evolving immunotherapy landscape and state of the science in lung cancer, including in locally advanced and earlier stages of NSCLC, Review key clinical trials assessing immunotherapies and immune-based combinations in stage III and earlier stages of lung cancer, and available data from such trials, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Determine the best treatment approaches for patients with stage III or earlier lung cancer as part of clinical practice or clinical trials based on the latest evidence, recommendations, patient needs and preferences, and effective multidisciplinary collaboration and coordination of care.